Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLAAG Protocol in Refractory/Relapsed AML and MDS
NCT03356080Phase 2Unknown
- Sponsor
- Shanghai Tongren Hospital
- Start
- Jul 2017
- Primary completion
- Jul 2019
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, cytarabine, tretinoin, filgrastim in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Shanghai Tongren Hospital. Status: unknown.
02
Drugs
decitabinecytarabinetretinoinfilgrastim
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03356080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356080.